AR056786A1 - Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com - Google Patents

Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com

Info

Publication number
AR056786A1
AR056786A1 ARP060104898A ARP060104898A AR056786A1 AR 056786 A1 AR056786 A1 AR 056786A1 AR P060104898 A ARP060104898 A AR P060104898A AR P060104898 A ARP060104898 A AR P060104898A AR 056786 A1 AR056786 A1 AR 056786A1
Authority
AR
Argentina
Prior art keywords
prepare
imidazo
pharmaceutically acceptable
composite
pyridin
Prior art date
Application number
ARP060104898A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR056786A1 publication Critical patent/AR056786A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un compuesto de 1H-imidazo[4,5-c]piridin-2-ilo que es seleccionado de: 4-(2-(4-amino-1,2,5-oxadiazol-3-il)-1-etil-7-{[(3S)-3-piperidinilmetil]oxi}-1H-imidazo[4,5-c]piridin-4-il)-2-metil-3-butin-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-il)-1-etil-7- {[(2S)-2-tiomorfolinilmetil]oxi}-1H-imidazo[4,5-c]piridin-4-il)-2-metil-3-butin-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-il)-1-etil-7-{[(2S)-2-morfolinilmetil]oxi}-1H-imidazo[4,5-c]piridin-4-il)-2-metil-3-butin-2-ol; y 4-[2-(4-amino-1,2,5-oxadiazol-3- il)-1-etil-7-{[(2R)-6metil-2-morfolinil]metil}oxi)-1H-imidazo[4,5-c]piridin-4-il)-2-metil-3-butin-2-ol; y/o sus sales, hidratos, solvatos y profármacos farmacéuticamente aceptables. Composicion farmacéutica que lo comprende y un vehículo farmacéuticamente aceptable, y procedimiento para preparar dicha composicion que comprende poner el compuesto de formula (1) y/o una de sus sales, hidratos, solvatos o profármacos farmacéuticamente aceptables en asociacion con un vehículo farmacéuticamente aceptable. Uso de una cantidad terapéuticamente eficaz de un compuesto de formula (1) y/o una de sus sales, hidratos, solvatos o profármacos farmacéuticamente aceptables, para preparar un medicamento util para tratar o reducir la gravedad de una enfermedad o estado patologico seleccionado de cáncer y artritis en un mamífero que lo necesita, mediante la administracion a dicho mamífero de dicho compuesto. Uso de una combinacion que comprende una cantidad terapéuticamente eficaz de: a) un compuesto de la formula (1) y/o una de sus sales, hidratos, solvatos o profármacos farmacéuticamente aceptables; y b) al menos un agente antineoplásico, para preparar un medicamento para tratar cáncer en un mamífero que lo necesita, mediante la administracion de la combinacion a dicho mamífero, y dicha combinacion farmacéutica.
ARP060104898A 2005-11-10 2006-11-08 Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com AR056786A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73595505P 2005-11-10 2005-11-10
US77228906P 2006-02-10 2006-02-10
US82692806P 2006-09-26 2006-09-26

Publications (1)

Publication Number Publication Date
AR056786A1 true AR056786A1 (es) 2007-10-24

Family

ID=38049129

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104898A AR056786A1 (es) 2005-11-10 2006-11-08 Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com

Country Status (16)

Country Link
US (1) US20100056523A1 (es)
EP (1) EP1948188A4 (es)
JP (1) JP2009516653A (es)
KR (1) KR20080067646A (es)
AP (1) AP2008004442A0 (es)
AR (1) AR056786A1 (es)
AU (1) AU2006315805A1 (es)
BR (1) BRPI0618309A2 (es)
CA (1) CA2629429A1 (es)
EA (1) EA200801301A1 (es)
EC (1) ECSP088425A (es)
IL (1) IL190968A0 (es)
MA (1) MA29935B1 (es)
NO (1) NO20082414L (es)
TW (1) TW200736260A (es)
WO (1) WO2007058850A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227616A1 (en) * 2005-11-10 2009-09-10 Smithkline Beecham Corporation, A Corporation Inhibitors of akt activity
KR20220008944A (ko) 2008-01-18 2022-01-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102027371A (zh) * 2008-05-16 2011-04-20 塞尔卓姆股份公司 Parp相互作用分子的鉴定方法和parp蛋白的纯化方法
EP2315751A1 (en) * 2008-06-26 2011-05-04 Amgen Inc. Alkynyl alcohols as kinase inhibitors
EP2370424A1 (en) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2604066C2 (ru) 2008-12-19 2016-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразина, используемые в качестве ингибиторов киназы atr
MX2012013082A (es) 2010-05-12 2013-05-09 Vertex Pharma Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピラジン
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2585468A1 (en) 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
KR20130041962A (ko) * 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
CA2827161A1 (en) 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
AU2012240030A1 (en) 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
SG11201401093WA (en) 2011-09-30 2014-04-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2751099B1 (en) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071085A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RS56673B1 (sr) 2012-04-05 2018-03-30 Vertex Pharma Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SI3808749T1 (sl) 2012-12-07 2023-07-31 Vertex Pharmaceuticals Incorporated Pirazolo(1,5-A)pirimidini za uporabo kot zaviralci ATR kinaze pri zdravljenju rakavih bolezni
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
US9718811B2 (en) 2013-06-26 2017-08-01 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (S)-enantiomer of mepazine
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
RU2687276C2 (ru) 2013-12-06 2019-05-13 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные для использования в качестве ингибиторов atr киназы
NZ764151A (en) 2014-06-05 2023-12-22 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
EA033237B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 화합물
JP6616411B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
CN112888440A (zh) 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic

Also Published As

Publication number Publication date
EP1948188A2 (en) 2008-07-30
EA200801301A1 (ru) 2009-02-27
JP2009516653A (ja) 2009-04-23
CA2629429A1 (en) 2007-05-24
WO2007058850A2 (en) 2007-05-24
ECSP088425A (es) 2008-06-30
TW200736260A (en) 2007-10-01
WO2007058850A3 (en) 2009-04-30
KR20080067646A (ko) 2008-07-21
AP2008004442A0 (en) 2008-04-30
IL190968A0 (en) 2009-02-11
NO20082414L (no) 2008-08-05
AU2006315805A1 (en) 2007-05-24
US20100056523A1 (en) 2010-03-04
MA29935B1 (fr) 2008-11-03
BRPI0618309A2 (pt) 2011-08-23
EP1948188A4 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
AR056786A1 (es) Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
JP5345842B2 (ja) プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
CO6160236A2 (es) Inhibidor de quinasa
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
AU2013269809B2 (en) Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
BRPI0115910B8 (pt) medicamento compreendendo 5-[(r)-2-(5,6-dietil-indan-2ilamino)-1-hidróxi-etil]-8-hidróxi-1h-quinolin-2-ona e corticóides para o tratamento de doencas inflamatórias ou obstrutivas das vias aéreas
EP3706741A1 (en) Pharmaceutical composition and use thereof
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
KR101575706B1 (ko) 암 치료용 선택적인 ｅｐ４ 수용체 길항제
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
EP3129375A1 (en) Asparagine endopeptidase (aep) inhibitors for managing cancer and compositions related thereto
ATE330928T1 (de) Substituierte chalkone als arzneimitteln
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
CN107531685B (zh) 具有抗肿瘤活性的化合物

Legal Events

Date Code Title Description
FB Suspension of granting procedure